Pre-Made Asunercept Biosimilar, Fusion Protein targeting FASLG/CD178 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting ALPS1B/APT1LG1/APTL/CD95-L/CD95L/FASL/TNFSF6/TNLG1A for drug discovery and mechanism of action (MOA) research

Pre-Made Asunercept Biosimilar, Fusion Protein targeting FASLG/CD178 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting ALPS1B/APT1LG1/APTL/CD95-L/CD95L/FASL/TNFSF6/TNLG1A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Asunercept (INN; development code APG11) is a soluble CD95-Fc fusion protein which is in clinical development for the treatment of glioblastoma multiforme (GBM) and myelodysplastic syndromes (MDS).[1] Asunercept has been granted orphan drug status for the treatment of GBM and MDS in the EU and the US.[2][3][4] It has also received PRIME designation by the European Medicines Agency (EMA) for the treatment of GBM.[5]

Asunercept is a soluble CD95-Fc fusion protein for the treatment of glioblastoma multiforme (GBM) and myelodysplastic syndromes (MDS). Asunercept blocks the CD95¨Cligand (CD95L) from binding to the CD95-receptor (CD95), which induces apoptosis. In oncology, this blockade is intended to prevent the killing of activated T cells that can be induced by tumor-associated macrophages (TAMs), endothelial cells, or fibroblasts. In MDS, CD95L-signaling is a negative regulator of erythrocyte production in the bone marrow and its blockade has been shown to rescue erythroid progenitors.